No need to login to view prices!
|Create new account|
Due to technical maintenance the BIOKÉ webshop is closed until November 15th, 2020. We apologize for any inconvenience caused.
Developing novel methods to screen antivirals is important for creating broad-spectrum anti-viral drugs and vaccines. The accurate measurement of viral activity plays an essential role for viral vaccine development and infectious disease studies. Find out why the rapid, sensitive, and high throughput xCELLigence Real-Time Cell Analysis Assay is ideal for infectious viral assays.
Conventional methods to measure virus and neutralizing antibody titers such as plaque assays, plaque reduction neutralization tests (PRNT), immunofluorescence foci assays (IFA), or interferon CPE assays are:
Conventional endpoint assays are labor intensive, time consuming, and difficult to reproduce, since different cell types and cell densities, as well as viral strains, serotypes, and mutations can cause plaque formation rates and sizes to vary dramatically.
Endpoint assays do not provide an assessment or quantification of the full virus life cycle.
Suboptimal selection of a single assay endpoint can result in inaccurate calculation of viral titer and lytic activity.